Aside from standard chemotherapy agents, for early hormone receptor (HR)-positive breast cancer, current guidelines recommend endocrine therapy in the form of GnRH analogues, which may be combined with tamoxifen, a selective estrogen receptor modulator [3]. The gene discussed is GNRH1; the disease is breast carcinoma.